MyMD Pharmaceuticals Enrolls First Patient in Stage 2 Professional Trial of MYMD-1 as a Therapy for Delaying Aging as well as Extending Healthy And Balanced Lifespan

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc – Stock Price, Quote and News (” MyMD” or “the Company”), a professional phase pharmaceutical firm devoted to expanding healthy and balanced life expectancy, today announced that the very first patient has actually been signed up in the Company’s Phase 2 clinical trial of lead prospect MYMD-1, an oral immune regulator drug, as a therapy for delaying aging and expanding healthy and balanced life expectancy.

The primary endpoint for the Phase 2 double-blind, placebo-controlled professional trial is to attain a reduction in the circulating degrees of (TNF-α), tumor necrosis aspect receptor I (TNFRI) as well as IL-6. TNF-α and IL-6 are the proteins in the body that trigger swelling and aid trigger the procedure of aging. The secondary steps of the test will be the safety and security, tolerability, and pharmacokinetics in this populace of individuals.

” In a Stage 1 medical test of MYMD-1, we showed the drug’s statistically substantial efficiency in reducing levels of TNF-α, a key player in triggering pathological aging, in the blood. The FDA has actually accepted TNF-α reduction as the main endpoint for our Phase 2 study, which our team believe settings us well for a successful Stage 2 result,” stated Chris Chapman, M.D., President, Director as well as Chief Medical Police Officer of MyMD. “The initiation of person enrollment in this research advances our mission to slow down the aging process, stop loss of muscle mass cells in aging, limitation frailty, as well as extend healthy lifespan.”

MyMD has mentioned that there are no FDA-approved drugs for dealing with aging problems and also prolonging healthy life expectancy humans, a market anticipated to be a minimum of $600 billion by 20251 according to a significant investment financial institution. TNF-α blockers are one of the most proposed drugs by revenue, a worldwide market of roughly $40 billion annually,2 and, according to Nature Aging journal,3 a stagnation in maturing that would certainly raise life expectancy by one year deserves $38 trillion and by ten years is worth $367 trillion.

In addition to aging, MYMD-1’s unique action in controling the immune system and treating chronic inflammation is being created for the therapy of autoimmune illness, consisting of rheumatoid joint inflammation (RA), numerous sclerosis (MS), diabetes, and also inflammatory digestive tract illness.

” We intend to start creating methods for a Phase 2 pilot research of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The rising frequency of rheumatoid arthritis as well as other autoimmune as well as inflammatory illness are driving need for TNF inhibitors like MYMD-1, as well as we believe our orally provided drug with really reduced poisoning would be turbulent to the $60 billion market for RA if approved by the FDA for this indicator.”

Rheumatoid arthritis influences approximately 40 million individuals worldwide.4.

Concerning MYMD-1.

Initially established for autoimmune diseases, MYMD-1’s primary purpose is to slow down the aging process, prevent sarcopenia and also frailty, and expand healthy life-span. Since it can cross the blood-brain obstacle and get to the main nerve system (CNS), MYMD-1 is also placed to be a possible therapy for brain-related problems. Its device of action and also efficacy in diseases consisting of numerous sclerosis (MS) as well as thyroiditis have actually been researched through collaborations with a number of academic institutions. MYMD-1 is likewise revealing promise in pre-clinical studies as a prospective therapy for article- COVID-19 issues and also as an anti-fibrotic and also anti-proliferation restorative.

MYMD-1 has actually revealed performance in pre-clinical research studies in regulating the body immune system by executing as a selective prevention of tumor death factor-alpha (TNF-α), a chauffeur of chronic inflammation. Unlike other therapies, MYMD-1 has been displayed in these pre-clinical research studies to uniquely block TNF-α when it becomes overactivated in autoimmune diseases and also cytokine tornados, but not block it from doing its regular task of being a first responder to any routine type of modest infection. MYMD-1’s ease of oral dosing is an additional differentiator compared to currently available TNF-α blockers, all of which call for delivery by shot or infusion. No approved TNF prevention has ever been dosed by mouth. Additionally, the drug is not immunosuppressive and has not been revealed to create the serious negative effects typical with conventional therapies that deal with inflammation.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a medical phase pharmaceutical firm devoted to expanding healthy lifespan, is concentrated on developing 2 unique restorative systems that treat the reasons for disease rather than only addressing the signs and symptoms. MYMD-1 is a medicine system based upon a medical phase tiny molecule that regulates the body immune system to manage TNF-α, which drives chronic inflammation, and also other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to delay aging, rise longevity, and also treat autoimmune diseases as well as COVID-19- connected anxiety. The Firm’s second drug system, Supera-CBD, is being created to deal with persistent pain, dependency and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and also is being created to deal with and improve upon the swiftly growing CBD market, which includes both FDA accepted medicines as well as CBD items not currently managed as medications. To find out more, visit www.mymd.com.